Key molecular pathways affected by glaucoma pathology: Is predictive diagnosis possible?

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 237-244

  Golubnitschaja, Olga ^a,b   Yeghiazaryan, Kristina ^a,b   Flammer, Josef ^b,c  

^a UNIVERSITY OF BONN   (Germany)

^b Preventive and Personalised Medicine   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Blood biomarkers; Early predictive diagnosis; Glaucoma; Personalised medicine; Specific molecular profiles; Targeted preventive measures

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CD31 ANTIGEN; GELATINASE B; HEAT SHOCK PROTEIN 27;

APOPTOSIS; BLOOD BRAIN BARRIER; CELL ADHESION; CELLULAR STRESS RESPONSE; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DISEASE MARKER; DNA REPAIR; EARLY DIAGNOSIS; ENERGY METABOLISM; EYE BLOOD FLOW; GENE EXPRESSION PROFILING; GENETIC RISK; GLAUCOMA; GLAUCOMATOUS OPTIC NEUROPATHY; HUMAN; INTRAOCULAR PRESSURE; LEUKOCYTE; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; MULTIDRUG RESISTANCE; NEUROPATHOLOGY; NON INVASIVE MEASUREMENT; PREVENTION STUDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE REGENERATION; TRANSCRIPTION REGULATION;

EID: 79953052401     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0031-4     Document Type: Review

References (60)

1. Golubnitschaja-Labudova O, Liu R, Decker C, et al. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000; 21: 867-76.
2. de la Monte SM, Xu YY, Hutchins GM, et al. Developmental patterns of neuronal thread protein gene expression in Down syndrome. J Neurol Sci. 1996; 135: 118-25.
3. Tatton W, Chen D, Chalmers-Redman R, et al. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003; 48: S25-37.
4. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996; 80: 389-93.
5. Flammer J. Glaucoma. A guide for patients. An introduction for care-providers. A quick reference. Hogrefe & Huber Publishers; 2003.
6. Gugleta K, Orgül S, Flammer J. Asymmetry in intraocular pressure and retinal nerve fiber layer thickness in normal-tension glaucoma. Ophthalmologica. 1999; 213: 219-23.
7. Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica. 1999; 213: 76-96.
8. Reddy AB, Panicker SG, Mandal AK, et al. Identification of R368H as a predominant CYP1B1 allele causing primary congenital glaucoma in Indian patients. Investig Ophthalmol Vis Sci. 2003; 44: 4200-3.
9. Kanagavalli J, Krishnadas SR, Pandaranayaka E, et al. Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients. Mol Vis. 2003; 14: 606-14.
10. Gong G, Kosoko-Lasaki O, Haynatzki GR, et al. Genetic dissection of myocilin glaucoma. Hum Mol Genet. 2004; 3: R91-102.
11. Mardin CY, Velten I, Ozbey S, et al. A GLC1A gene Gln368Stop mutation in a patient with normal-tension open-angle glaucoma. J Glaucoma. 1999; 8: 154-6.
12. Colomb E, Kaplan J, Garchon HJ. Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France. Hum Mutat. 2003; 22: 496.
13. Howell N. LHON and other optic nerve atrophies: the mitochondrial connection. Dev Ophthalmol. 2003; 37: 94-108.
14. Leung YF, Fan BJ, Lam DS, et al. Different optineurin mutation pattern in primary open-angle glaucoma. Investig Ophthalmol Vis Sci. 2003; 44: 3880-4.
15. Mackey DA, Craig JE. Predictive DNA testing for glaucoma: reality in 2003. Ophthalmol Clin N Am. 2003; 16: 639-45.
16. Polansky JR. Current perspectives on the TIGR/MYOC gene (Myocilin) and glaucoma. Ophthalmol Clin North Am. 2003; 16: 515-27. v-vi.
17. Panicker SG, Mandal AK, Reddy AB, et al. Correlations of genotype with phenotype in Indian patients with primary congenital glaucoma. Investig Ophthalmol Vis Sci. 2004; 45: 1149-56.
18. Herndon LW, Challa P, Allingham RR. Glaucoma in Ghana, West Africa: clinical features and the role of mutations in Myocilin. Ophthalmol Clin N Am. 2003; 16: 631-7.
19. Bruttini M, Longo I, Frezzotti P, et al. Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch Ophthalmol. 2003; 121: 1034-8.
20. Melki R, Idhajji A, Driouiche S, et al. Mutational analysis of the Myocilin gene in patients with primary open-angle glaucoma in Morocco. Ophthalmic Genet. 2003; 24: 153-60.
21. Wiggs JL, Auguste J, Allingham RR, et al. Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma. Arch Ophthalmol. 2003; 121: 1181-3.
22. Sripriya S, Uthra S, Sangeetha R, et al. Low frequency of myocilin mutations in Indian primary open-angle glaucoma patients. Clin Genet. 2004; 65: 333-7.
23. Yeghiazaryan K, Flammer J, Orgül S, et al. Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis. 2009; 15: 2339-48.
24. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. The EPMA Journal. 2010; 2.
25. Yang J, Patil RV, Yu H, et al. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am J Ophthalmol. 2001; 131: 421-6.
26. Grus FH, Joachim SC, Bruns K, et al. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Investig Ophthalmol Vis Sci. 2006; 47: 968-76.
27. Tomarev SI, Wistow G, Raymond V, et al. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Investig Ophthalmol Vis Sci. 2003; 44: 2588-96.
28. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucoma? Surv Ophthalmol. 2007; 52 Suppl 2: S162-73.
29. Golubnitschaja O, Yeghiazaryan K, Orgül S, et al. What are the biomarkers for Glaucoma? In: Golubnitshaja O, editor. Predictive diagnostics and personalized treatment: dream or reality. New York: Nova Science; 2009. p. 375-96.
30. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, et al. Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin Appl. 2007; 1: 1316-23.
31. Tezel G, Yang X, Cai J. Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Investig Ophthalmol Vis Sci. 2005; 46: 3177-87.
32. Ahmed F, Brown KM, Stephan DA, et al. Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Investig Ophthalmol Vis Sci. 2004; 45: 1247-58.
33. Wunderlich K, Golubnitschaja O, Pache M, et al. Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Mol Vis. 2002; 8: 431-5.
34. Golubnitschaja O, Fountoulakis M. Gene hunting by substractive hybridisation in Down syndrome. Correlation with proteomics analysis. In: Mandel S, editor. Genomics, proteomics and the nervous system. 3rd ed. Berlin-Heidelberg: Springer; 2007.
35. Moenkemann H, Flammer J, Wunderlich K, et al. Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals. Amino Acids. 2005; 28: 199-205.
36. Golubnitschaja O, Wunderlich K, Decker C, et al. Molecular imaging of perfusion disturbances in glaucoma. Amino Acids. 2002; 23: 293-9.
37. Grieshaber MC, Flammer J. Does the blood-brain-barrier play a role in Glaucoma? Surv Ophthalmol. 2007; 52 Suppl 2: S144-54.
38. Golubnitschaja O, Yeghiazaryan K, Liu R, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma. 2004; 13: 66-72.
39. Diskin S, Kumar J, Cao Z, et al. Detection of differentially expressed glycogenes in trabecular meshwork of eyes with primary open-angle glaucoma. Investig Ophthalmol Vis Sci. 2006; 47: 1491-9.
40. Bhattacharya SK, Rockwood EJ, Smith SD, et al. Proteomics reveal Cochlin deposits associated with glaucomatous trabecular meshwork. J Biol Chem. 2005; 280: 6080-4.
41. Fleenor DL, Pang IH, Clark AF. Involvement of AP-1 in interleukin-1alpha-stimulated MMP-3 expression in human trabecular meshwork cells. Investig Ophthalmol Vis Sci. 2003; 44: 3494-501.
42. Pang IH, Fleenor DL, Hellberg PE, et al. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Investig Ophthalmol Vis Sci. 2003; 44: 3502-10.
43. Mohan R, Rinehart WB, Bargagna-Mohan P, et al. Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling. J Biol Chem. 1998; 273: 25903-14.
44. Esser J, Esser P, Mietz H, et al. Multidrug resistance-associated proteins in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2000; 238: 727-32.
45. Yeghiazaryan K, Flammer J, Wunderlich K, et al. An enhanced expression of ABC 1 transporter in circulating leukocytes as a potential molecular marker for the diagnostics of glaucoma. Amino Acids. 2005; 28: 207-11.
46. Joyce CW, Amar MJ, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA. 2002; 99: 407-12.
47. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003; 107: 2944-8.
48. Pechere-Bertschi A, Sunaric-Megevand G, Haefliger IO, et al. Renal sodium handling in patients with normal pressure glaucoma. Clin Sci (Lond). 2007; 112: 337-44.
49. Schwartz B, Abrahamson R, Takamoto T, et al. Association of ocular pressure and optic disc cup volume with red blood cell sodium-potassium ATPase inhibition. Curr Eye Res. 2000; 21: 897-905.
50. Salomon P, Mysiak A, Halawa B. Sodium efflux through lymphocytic cell membranes in patients with acute myocardial infarction. Pol Arch Med Wewn. 1998; 100: 543-50.
51. Stark G. Functional consequences of oxidative membrane damage. J Membr Biol. 2005; 205: 1-16.
52. Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid. 1995; 5: 481-92.
53. Valdemarsson S, Ikomi-Kumm J, Monti M. Increased lymphocyte thermogenesis in hyperthyroid patients. Role of Na/K pump function. Evaluation of aerobic/anaerobic metabolism. Acta Endocrinol (Copenh). 1992; 126: 291-5.
54. Bagrov AY, Dmitrieva RI, Fedorova OV, et al. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity. Am J Hypertens. 1996; 9: 982-90.
55. van den Bergh WM, Dijkhuizen RM, Rinkel GJ. Potentials of magnesium treatment in subarachnoid haemorrhage. Magnes Res. 2004; 17: 301-13.
56. Kotikoski H, Moilanen E, Vapaatalo H, et al. Biochemical markers of the L-arginine-nitric oxide pathway in the aqueous humour in glaucoma patients. Acta Ophthalmol Scand. 2002; 80: 191-5.
57. Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101: 454-60.
58. Souchier M, Buron N, Lafontaine PO, et al. Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery? Br J Ophthalmol. 2006; 90: 1366-9.
59. Golubnitschaja O, Flammer J. International Patent No. IB02/00648.
60. Golubnitschaja O, Flammer J. What are the biomarkers for glaucoma? Surv Ophthalmol. 2007; 52: S155-61.